Extracellular Vesicles from Mesenchymal Stromal Cells for the Treatment of Inflammation-Related Conditions

Ryan, ST; Hosseini-Beheshti, E; Afrose, D; Ding, X; Xia, B; Grau, GE; Little, CB; McClements, L; Li, JJ

Extracellular Vesicles from Mesenchymal Stromal Cells for the Treatment of Inflammation-Related Conditions

Ryan, ST Hosseini-Beheshti, E Afrose, D Ding, X Xia, B Grau, GE Little, CB McClements, L

Li, JJ

Permalink

Publisher:: MDPI
Publication Type:: Journal Article
Citation:: International Journal of Molecular Sciences, 2021, 22, (6), pp. 1-34
Issue Date:: 2021-03-16

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (1.62 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Ryan, ST
dc.contributor.author	Hosseini-Beheshti, E
dc.contributor.author	Afrose, D
dc.contributor.author	Ding, X
dc.contributor.author	Xia, B
dc.contributor.author	Grau, GE
dc.contributor.author	Little, CB
dc.contributor.author	McClements, L https://orcid.org/0000-0002-4911-1014
dc.contributor.author	Li, JJ
dc.date.accessioned	2021-07-27T07:38:23Z
dc.date.available	2021-03-12
dc.date.available	2021-07-27T07:38:23Z
dc.date.issued	2021-03-16
dc.identifier.citation	International Journal of Molecular Sciences, 2021, 22, (6), pp. 1-34
dc.identifier.issn	1422-0067
dc.identifier.issn	1422-0067
dc.identifier.uri	http://hdl.handle.net/10453/149947
dc.description.abstract	Over the past two decades, mesenchymal stromal cells (MSCs) have demonstrated great potential in the treatment of inflammation-related conditions. Numerous early stage clinical trials have suggested that this treatment strategy has potential to lead to significant improvements in clinical outcomes. While promising, there remain substantial regulatory hurdles, safety concerns, and logistical issues that need to be addressed before cell-based treatments can have widespread clinical impact. These drawbacks, along with research aimed at elucidating the mechanisms by which MSCs exert their therapeutic effects, have inspired the development of extracellular vesicles (EVs) as anti-inflammatory therapeutic agents. The use of MSC-derived EVs for treating inflammation-related conditions has shown therapeutic potential in both in vitro and small animal studies. This review will explore the current research landscape pertaining to the use of MSC-derived EVs as anti-inflammatory and pro-regenerative agents in a range of inflammation-related conditions: osteoarthritis, rheumatoid arthritis, Alzheimer's disease, cardiovascular disease, and preeclampsia. Along with this, the mechanisms by which MSC-derived EVs exert their beneficial effects on the damaged or degenerative tissues will be reviewed, giving insight into their therapeutic potential. Challenges and future perspectives on the use of MSC-derived EVs for the treatment of inflammation-related conditions will be discussed.
dc.format	Electronic
dc.language	eng
dc.publisher	MDPI
dc.relation	http://purl.org/au-research/grants/nhmrc/1120249
dc.relation.ispartof	International Journal of Molecular Sciences
dc.relation.isbasedon	10.3390/ijms22063023
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	0399 Other Chemical Sciences, 0604 Genetics, 0699 Other Biological Sciences
dc.subject.classification	Chemical Physics
dc.subject.mesh	Mesenchymal Stem Cells
dc.subject.mesh	Animals
dc.subject.mesh	Humans
dc.subject.mesh	Inflammation
dc.subject.mesh	Models, Biological
dc.subject.mesh	Extracellular Vesicles
dc.subject.mesh	Animals
dc.subject.mesh	Extracellular Vesicles
dc.subject.mesh	Humans
dc.subject.mesh	Inflammation
dc.subject.mesh	Mesenchymal Stem Cells
dc.subject.mesh	Models, Biological
dc.title	Extracellular Vesicles from Mesenchymal Stromal Cells for the Treatment of Inflammation-Related Conditions
dc.type	Journal Article
utslib.citation.volume	22
utslib.location.activity	Switzerland
utslib.for	0399 Other Chemical Sciences
utslib.for	0604 Genetics
utslib.for	0699 Other Biological Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	/University of Technology Sydney/Strength - IBMD - Initiative for Biomedical Devices
utslib.copyright.status	open_access	*
dc.date.updated	2021-07-27T07:38:19Z
pubs.issue	6
pubs.publication-status	Published
pubs.volume	22
utslib.citation.issue	6

Abstract:

Over the past two decades, mesenchymal stromal cells (MSCs) have demonstrated great potential in the treatment of inflammation-related conditions. Numerous early stage clinical trials have suggested that this treatment strategy has potential to lead to significant improvements in clinical outcomes. While promising, there remain substantial regulatory hurdles, safety concerns, and logistical issues that need to be addressed before cell-based treatments can have widespread clinical impact. These drawbacks, along with research aimed at elucidating the mechanisms by which MSCs exert their therapeutic effects, have inspired the development of extracellular vesicles (EVs) as anti-inflammatory therapeutic agents. The use of MSC-derived EVs for treating inflammation-related conditions has shown therapeutic potential in both in vitro and small animal studies. This review will explore the current research landscape pertaining to the use of MSC-derived EVs as anti-inflammatory and pro-regenerative agents in a range of inflammation-related conditions: osteoarthritis, rheumatoid arthritis, Alzheimer's disease, cardiovascular disease, and preeclampsia. Along with this, the mechanisms by which MSC-derived EVs exert their beneficial effects on the damaged or degenerative tissues will be reviewed, giving insight into their therapeutic potential. Challenges and future perspectives on the use of MSC-derived EVs for the treatment of inflammation-related conditions will be discussed.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/149947